Skip to main content
. 2022 Apr 16;6(6):bvac065. doi: 10.1210/jendso/bvac065

Table 2.

Distribution of participants in each randomized dose group across strata of achieved serum 25(OH)D concentration

200 IU/d
(N = 314)
1000 IU/d
(N = 195)
2000 IU/d
(N = 64)
4000 IU/d
(N = 64)
Level at 3 mo, ng/mL
 ≤ 29 214 (68.2%) 67 (34.4%) 15 (23.4%) 3 (4.7%)
 30-39 96 (30.6%) 101 (51.8%) 33 (51.6%) 12 (18.8%)
 > 40 4 (1.3%) 27 (13.8%) 16 (25.0%) 49 (76.6%)
Absolute change from BL to 3 mo (FU-BL, ng/mL)
 Lower 25%: -9 to 2 119 (37.9%) 22 (11.3%) 5 (7.8%) 1 (1.6%)
 Middle 50%: 3-14 179 (57.0%) 129 (66.2%) 33 (51.6%) 9 (14.1%)
 Upper 25%: 15-66 16 (5.1%) 44 (22.6%) 26 (40.6%) 54 (84.4%)
Relative change from BL to 3 months ((FU-BL)/BL, (%))
 Lower 25%: -36 to 10 127 (40.4%) 26 (13.3%) 5 (7.8%) 1 (1.6%)
 Middle 50%: 11-70 152 (48.4%) 125 (64.1%) 32 (50.0%) 11 (17.2%)
 Upper 75%: 71-455 35 (11.1%) 44 (22.6%) 27 (42.2%) 52 (81.3%)

To convert 25(OH)D ng/ml to nmol/L, multiply ng/mL by 2.5.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BL, baseline; FU, follow-up.